Trial NCT01881789

View at ClinicalTrials.gov 
Org. Study IDs: OPZ003
Secondary IDs: 20130410

Last trial update was posted on 2022-11-14

MeSH Interventions

Cyclophosphamide Dexamethasone Lenalidomide

MeSH Conditions

Multiple Myeloma Neoplasms, Plasma Cell

Other Conditions


Stopping Reasons

A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID